Width of the third ventricle as a highly-sensitive biomarker in chronic progressive neuro-Behçet's disease.

Behcet Syndrome / diagnosis Biomarkers Disease Progression Humans Magnetic Resonance Imaging Retrospective Studies Third Ventricle
Behçet's disease Brain atrophy Infliximab Methotrexate Neuro-Behçet's disease Third ventricle

Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 Feb 2021
Historique:
received: 02 06 2020
revised: 16 12 2020
accepted: 17 12 2020
pubmed: 29 12 2020
medline: 15 5 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Chronic progressive neuro-Behçet's disease (CPNBD) is characterized by slowly progressive cognitive decline, cerebellar ataxia, and brainstem atrophy without acute encephalomeningitis. To evaluate the progression of CPNBD during treatment, we conducted a retrospective, longitudinal comparative analysis of the clinical features and brain magnetic resonance imaging (MRI) in patients with CPNBD. We classified participants into three groups: NBD with acute encephalomeningitis alone (Group A, 8 patients with acute neuro-Behçet's disease [ANBD]), primary progressive CPNBD (Group B, 3 patients), and a combination of acute encephalomeningitis, and chronic progression (Group C, 2 patients). Routine laboratory tests and monthly rate of enlargement of the width of the third ventricle (ΔWTVm) and relative value of ΔWTVm to the transverse cerebral diameter (ΔWTVIm) were statistically evaluated. Although higher cell count values and interleukin-6 concentration in the cerebrospinal fluid were observed in ANBD, both ΔWTVm (p = 0.008) and ΔWTVIm (p = 0.008) were significantly larger in CPNBD phase than in the ANBD phase. Effective treatment for CPNBD seemed to reduce ΔWTVm and ΔWTVIm in some patients. Sequential evaluation of WTV in patients with CPNBD is a highly sensitive candidate biomarker of early diagnosis and treatment efficacy.

Identifiants

DOI: 10.1016/j.jns.2020.117284 PMID: 33360732
pubmed: 33360732
pii: S0022-510X(20)30620-1
doi: 10.1016/j.jns.2020.117284
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117284

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Sunao Takahashi (S)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan. Electronic address: sutakahashi.nuro@tmd.ac.jp.

Nobuo Sanjo (N)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan. Electronic address: n-sanjo.nuro@tmd.ac.jp.

Shohei Miyamoto (S)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan; Department of General Internal Medicine, Asahi General Hospital, 1326, I, Asahi-shi, Chiba 289-2500, Japan.

Takaaki Hattori (T)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan. Electronic address: takaaki-hattori@umin.ac.jp.

Jun Oyama (J)

Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan. Electronic address: junoym@gmail.com.

Ukihide Tateishi (U)

Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan. Electronic address: ttisdrnm@tmd.ac.jp.

Takanori Yokota (T)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan. Electronic address: yokonuro@tmd.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vasculaires › Maladie de Behçet › Width of the third ventricle as a...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Width of the third ventricle as a...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Width of the third ventricle as a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Width of the third ventricle as a...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Width of the third ventricle as a...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Width of the third ventricle as a...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Ventricules cérébraux › Troisième ventricule › Width of the third ventricle as a...